JP2018537987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537987A5 JP2018537987A5 JP2018532036A JP2018532036A JP2018537987A5 JP 2018537987 A5 JP2018537987 A5 JP 2018537987A5 JP 2018532036 A JP2018532036 A JP 2018532036A JP 2018532036 A JP2018532036 A JP 2018532036A JP 2018537987 A5 JP2018537987 A5 JP 2018537987A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- mammal
- amino acid
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 86
- 230000002708 enhancing effect Effects 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 31
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 24
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 229960003624 creatine Drugs 0.000 claims description 13
- 239000006046 creatine Substances 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 10
- -1 nitrogen-containing organic acid Chemical class 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 102000008934 Muscle Proteins Human genes 0.000 claims description 8
- 108010074084 Muscle Proteins Proteins 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229960004203 carnitine Drugs 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 238000001243 protein synthesis Methods 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 230000014616 translation Effects 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 5
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000189 Arabinogalactan Polymers 0.000 claims description 4
- 239000001904 Arabinogalactan Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 241000978776 Senegalia senegal Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 235000019312 arabinogalactan Nutrition 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 150000001734 carboxylic acid salts Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 235000020776 essential amino acid Nutrition 0.000 claims description 2
- 239000003797 essential amino acid Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 230000037074 physically active Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000017854 proteolysis Effects 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022005112A JP2022064912A (ja) | 2015-12-18 | 2022-01-17 | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269573P | 2015-12-18 | 2015-12-18 | |
| US62/269,573 | 2015-12-18 | ||
| US201562273880P | 2015-12-31 | 2015-12-31 | |
| US62/273,880 | 2015-12-31 | ||
| PCT/US2016/067238 WO2017106687A1 (en) | 2015-12-18 | 2016-12-16 | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing a composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005112A Division JP2022064912A (ja) | 2015-12-18 | 2022-01-17 | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537987A JP2018537987A (ja) | 2018-12-27 |
| JP2018537987A5 true JP2018537987A5 (enExample) | 2020-01-30 |
Family
ID=57910110
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532036A Withdrawn JP2018537987A (ja) | 2015-12-18 | 2016-12-16 | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
| JP2022005112A Pending JP2022064912A (ja) | 2015-12-18 | 2022-01-17 | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005112A Pending JP2022064912A (ja) | 2015-12-18 | 2022-01-17 | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10888571B2 (enExample) |
| EP (1) | EP3389385A1 (enExample) |
| JP (2) | JP2018537987A (enExample) |
| BR (1) | BR112018012410B1 (enExample) |
| CA (1) | CA3008033A1 (enExample) |
| WO (1) | WO2017106687A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3008033A1 (en) * | 2015-12-18 | 2017-06-22 | Lonza, Inc. | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals |
| CN118178404A (zh) * | 2017-11-02 | 2024-06-14 | 生物风险投资有限责任公司 | 氨基酸补充剂在提高肌肉蛋白质合成中的用途 |
| KR102853179B1 (ko) * | 2019-03-06 | 2025-08-29 | 시엔펑 펑 | 동물사료 첨가제를 제조하기 위한 γ-4차 암모늄 부티레이트계 화합물의 용도 |
| EP4027990A4 (en) * | 2019-10-16 | 2023-10-18 | Capsugel Belgium NV | METHOD AND COMPOSITION FOR INCREASE SYNTHESIS OF MUSCLE PROTEIN |
| MX2022004515A (es) * | 2019-10-16 | 2022-07-12 | Capsugel Belgium Nv | Metodo y composicion para aumentar la sintesis de proteinas musculares. |
| DE102022114966A1 (de) | 2022-06-14 | 2023-12-14 | Alzchem Trostberg Gmbh | Wasserlösliches Kreatin-Agglomerat |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687782A (en) | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
| US4883672A (en) | 1988-04-29 | 1989-11-28 | Shug Austin L | Method for preventing diet induced carnitine deficiency in domesticated dogs and cats |
| AU3086897A (en) * | 1996-06-28 | 1998-01-21 | Ipr-Institute For Pharmaceutical Research Ag | Drug preparations, containing creatine with at least one salt of calcium, magnesium, manganese or zinc |
| US6232346B1 (en) * | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| US6159942A (en) | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
| IT1306173B1 (it) | 1999-07-23 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare. |
| CA2399319A1 (en) | 2000-01-25 | 2001-08-16 | Nathan D. Hamilton | Nutritional supplements for aged pets |
| US20030138547A1 (en) | 2002-01-22 | 2003-07-24 | Mars, Incorporated | Weight management system for animals |
| AU2005322015B2 (en) | 2004-12-29 | 2010-02-25 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
| US7645742B2 (en) * | 2005-06-22 | 2010-01-12 | Advocare International, L.P. | Composition for enhancing cellular energy |
| US20080085343A1 (en) * | 2006-09-14 | 2008-04-10 | Petty Holly T | Novel Low Allergenic Food Bar |
| WO2008115563A1 (en) * | 2007-03-19 | 2008-09-25 | University Of Florida Research Foundation, Inc. | Liquid nutrient composition for improving performance |
| US7790688B2 (en) * | 2008-01-11 | 2010-09-07 | Healthspan Solutions, Llc | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
| US8546369B2 (en) | 2008-05-30 | 2013-10-01 | Northern Innovations Holding Corp. | Salts of creatine imino sugar amides |
| FR2938733A1 (fr) | 2008-11-21 | 2010-05-28 | Holymark | Composition administrable par voie orale,en particulier pour personne pratiquant une activite physique et complement alimentaire renfermant une telle composition |
| US8784844B2 (en) | 2009-09-30 | 2014-07-22 | Lonza Ltd. | Arabinogalactan for enhancing the adaptive immune response |
| CA2835429A1 (en) | 2011-05-10 | 2012-11-15 | Nestec S.A. | Methods and compositions for promoting lean body mass growth |
| ITTO20121098A1 (it) | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| WO2015094772A1 (en) | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
| CA2951567C (en) | 2014-06-12 | 2023-10-31 | Lonza, Inc. | Method for decreasing skeletal muscle damage and/or oxidative stress in mammals |
| CA3008033A1 (en) * | 2015-12-18 | 2017-06-22 | Lonza, Inc. | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals |
-
2016
- 2016-12-16 CA CA3008033A patent/CA3008033A1/en active Pending
- 2016-12-16 BR BR112018012410-9A patent/BR112018012410B1/pt not_active IP Right Cessation
- 2016-12-16 US US15/381,731 patent/US10888571B2/en active Active
- 2016-12-16 WO PCT/US2016/067238 patent/WO2017106687A1/en not_active Ceased
- 2016-12-16 EP EP16831665.1A patent/EP3389385A1/en not_active Withdrawn
- 2016-12-16 JP JP2018532036A patent/JP2018537987A/ja not_active Withdrawn
-
2021
- 2021-01-08 US US17/144,556 patent/US20210205334A1/en not_active Abandoned
-
2022
- 2022-01-17 JP JP2022005112A patent/JP2022064912A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537987A5 (enExample) | ||
| JP2016516040A5 (enExample) | ||
| KR102464646B1 (ko) | (r)-2-아미노-3-페닐프로필 카바메이트의 제제 | |
| JP2022064912A5 (enExample) | ||
| J Geldenhuys et al. | Rationally designed multi-targeted agents against neurodegenerative diseases | |
| JP2018012722A5 (enExample) | ||
| BRPI0517662A (pt) | partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| JP2015528471A5 (enExample) | ||
| RU2015143836A (ru) | Лейцин и никотиновая кислота для снижения уровня липидов | |
| JP2017507973A5 (enExample) | ||
| FI3782617T3 (fi) | Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia | |
| JP2010521420A5 (enExample) | ||
| JP2014218522A5 (enExample) | ||
| JP2018521007A5 (enExample) | ||
| JP2015524664A (ja) | 有効成分をペレット化の間の分解から保護する方法 | |
| JP2020533296A5 (enExample) | ||
| NZ591204A (en) | Pharmaceutical compositions and methods for stabilizing the same | |
| JP2019501226A5 (enExample) | ||
| JP2020509072A5 (enExample) | ||
| JP5689458B2 (ja) | グルコサミンを包含する栄養補助食品を安定化させる方法 | |
| JP2004511498A5 (enExample) | ||
| JP2003504395A5 (enExample) | ||
| JP2015120758A5 (enExample) | ||
| JP2017008001A5 (enExample) |